APO Research
Talk to an analyst

APO RESEARCH · REPORT

Short-acting Insulin

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Short-acting Insulin Market Analysis and Forecast 2026-2032

29 December 2025199 pages

Choose your research edition.

Industry ResearchShort-acting Insulin Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Short-acting Insulin Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Short-acting Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Short-acting Insulin Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Short-acting Insulin Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Short-acting Insulin market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Short-acting Insulin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Short-acting Insulin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Short-acting Insulin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Short-acting Insulin is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Short-acting Insulin include Zhuhai United Pharmaceutical, Wanbang Biopharmaceuticals, Sinovac Biotech, HTBT, Tonghua Dongbao Pharmaceutical, Wockhardt, Sanofi, Pfizer and Novo Nordisk, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Short-acting Insulin, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Short-acting Insulin, also provides the sales of main regions and countries. Of the upcoming market potential for Short-acting Insulin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Short-acting Insulin sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Short-acting Insulin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Short-acting Insulin sales, projected growth trends, production technology, application and end-user industry.

Short-acting Insulin Segment by Company

Zhuhai United Pharmaceutical

Wanbang Biopharmaceuticals

Sinovac Biotech

HTBT

Tonghua Dongbao Pharmaceutical

Wockhardt

Sanofi

Pfizer

Novo Nordisk

Eli Lilly

Biocon Biologics

Bayer

BASF

Abbott Laboratories

Short-acting Insulin Segment by Type

Regular Insulin

Biosynthetic Human Insulin

Recombinant Human Insulin

Other

Short-acting Insulin Segment by Application

Type 2 Diabetes

Type 1 Diabetes

Gestational Diabetes

Complications of Diabetes

Other

Short-acting Insulin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Short-acting Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Short-acting Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Short-acting Insulin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Short-acting Insulin in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Short-acting Insulin manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Short-acting Insulin sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Short-acting Insulin Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Regular Insulin Major Manufacturers Table 3. Biosynthetic Human Insulin Major Manufacturers Table 4. Recombinant Human Insulin Major Manufacturers Table 5. Other Major Manufacturers Table 6. Global Short-acting Insulin Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Type 2 Diabetes Major Manufacturers Table 8. Type 1 Diabetes Major Manufacturers Table 9. Gestational Diabetes Major Manufacturers Table 10. Complications of Diabetes Major Manufacturers Table 11. Other Major Manufacturers Table 12. Short-acting Insulin Industry Trends Table 13. Short-acting Insulin Industry Drivers Table 14. Short-acting Insulin Industry Opportunities and Challenges Table 15. Short-acting Insulin Industry Restraints Table 16. Global Short-acting Insulin Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Short-acting Insulin Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Short-acting Insulin Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Short-acting Insulin Revenue Market Share by Region (2021-2026) Table 20. Global Short-acting Insulin Revenue Market Share by Region (2027-2032) Table 21. Global Short-acting Insulin Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 22. Global Short-acting Insulin Sales by Region (2021-2026) & (K Units) Table 23. Global Short-acting Insulin Sales by Region (2027-2032) & (K Units) Table 24. Global Short-acting Insulin Sales Market Share by Region (2021-2026) Table 25. Global Short-acting Insulin Sales Market Share by Region (2027-2032) Table 26. Global Short-acting Insulin Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Short-acting Insulin Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Short-acting Insulin Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Short-acting Insulin Sales Market Share by Manufacturers (2021-2026) Table 30. Global Short-acting Insulin Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Short-acting Insulin Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Short-acting Insulin Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Short-acting Insulin Manufacturers, Product Type & Application Table 34. Global Short-acting Insulin Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Short-acting Insulin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Short-acting Insulin Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Short-acting Insulin Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Short-acting Insulin Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Short-acting Insulin Revenue Market Share by Type (2021-2026) Table 41. Global Short-acting Insulin Revenue Market Share by Type (2027-2032) Table 42. Global Short-acting Insulin Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 43. Global Short-acting Insulin Sales by Type (2021-2026) & (K Units) Table 44. Global Short-acting Insulin Sales by Type (2027-2032) & (K Units) Table 45. Global Short-acting Insulin Sales Market Share by Type (2021-2026) Table 46. Global Short-acting Insulin Sales Market Share by Type (2027-2032) Table 47. Global Short-acting Insulin Price by Type (2021-2026) & (US$/Unit) Table 48. Global Short-acting Insulin Price by Type (2027-2032) & (US$/Unit) Table 49. Global Short-acting Insulin Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Short-acting Insulin Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Short-acting Insulin Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Short-acting Insulin Revenue Market Share by Application (2021-2026) Table 53. Global Short-acting Insulin Revenue Market Share by Application (2027-2032) Table 54. Global Short-acting Insulin Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 55. Global Short-acting Insulin Sales by Application (2021-2026) & (K Units) Table 56. Global Short-acting Insulin Sales by Application (2027-2032) & (K Units) Table 57. Global Short-acting Insulin Sales Market Share by Application (2021-2026) Table 58. Global Short-acting Insulin Sales Market Share by Application (2027-2032) Table 59. Global Short-acting Insulin Price by Application (2021-2026) & (US$/Unit) Table 60. Global Short-acting Insulin Price by Application (2027-2032) & (US$/Unit) Table 61. Zhuhai United Pharmaceutical Company Information Table 62. Zhuhai United Pharmaceutical Business Overview Table 63. Zhuhai United Pharmaceutical Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolio Table 65. Zhuhai United Pharmaceutical Recent Development Table 66. Wanbang Biopharmaceuticals Company Information Table 67. Wanbang Biopharmaceuticals Business Overview Table 68. Wanbang Biopharmaceuticals Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolio Table 70. Wanbang Biopharmaceuticals Recent Development Table 71. Sinovac Biotech Company Information Table 72. Sinovac Biotech Business Overview Table 73. Sinovac Biotech Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Sinovac Biotech Short-acting Insulin Product Portfolio Table 75. Sinovac Biotech Recent Development Table 76. HTBT Company Information Table 77. HTBT Business Overview Table 78. HTBT Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. HTBT Short-acting Insulin Product Portfolio Table 80. HTBT Recent Development Table 81. Tonghua Dongbao Pharmaceutical Company Information Table 82. Tonghua Dongbao Pharmaceutical Business Overview Table 83. Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolio Table 85. Tonghua Dongbao Pharmaceutical Recent Development Table 86. Wockhardt Company Information Table 87. Wockhardt Business Overview Table 88. Wockhardt Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Wockhardt Short-acting Insulin Product Portfolio Table 90. Wockhardt Recent Development Table 91. Sanofi Company Information Table 92. Sanofi Business Overview Table 93. Sanofi Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Sanofi Short-acting Insulin Product Portfolio Table 95. Sanofi Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Pfizer Short-acting Insulin Product Portfolio Table 100. Pfizer Recent Development Table 101. Novo Nordisk Company Information Table 102. Novo Nordisk Business Overview Table 103. Novo Nordisk Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Novo Nordisk Short-acting Insulin Product Portfolio Table 105. Novo Nordisk Recent Development Table 106. Eli Lilly Company Information Table 107. Eli Lilly Business Overview Table 108. Eli Lilly Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Eli Lilly Short-acting Insulin Product Portfolio Table 110. Eli Lilly Recent Development Table 111. Biocon Biologics Company Information Table 112. Biocon Biologics Business Overview Table 113. Biocon Biologics Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Biocon Biologics Short-acting Insulin Product Portfolio Table 115. Biocon Biologics Recent Development Table 116. Bayer Company Information Table 117. Bayer Business Overview Table 118. Bayer Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Bayer Short-acting Insulin Product Portfolio Table 120. Bayer Recent Development Table 121. BASF Company Information Table 122. BASF Business Overview Table 123. BASF Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. BASF Short-acting Insulin Product Portfolio Table 125. BASF Recent Development Table 126. Abbott Laboratories Company Information Table 127. Abbott Laboratories Business Overview Table 128. Abbott Laboratories Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Abbott Laboratories Short-acting Insulin Product Portfolio Table 130. Abbott Laboratories Recent Development Table 131. North America Short-acting Insulin Revenue by Type (2021-2026) & (US$ Million) Table 132. North America Short-acting Insulin Revenue by Type (2027-2032) & (US$ Million) Table 133. North America Short-acting Insulin Sales by Type (2021-2026) & (K Units) Table 134. North America Short-acting Insulin Sales by Type (2027-2032) & (K Units) Table 135. North America Short-acting Insulin Sales Price by Type (2021-2026) & (US$/Unit) Table 136. North America Short-acting Insulin Sales Price by Type (2027-2032) & (US$/Unit) Table 137. North America Short-acting Insulin Revenue by Application (2021-2026) & (US$ Million) Table 138. North America Short-acting Insulin Revenue by Application (2027-2032) & (US$ Million) Table 139. North America Short-acting Insulin Sales by Application (2021-2026) & (K Units) Table 140. North America Short-acting Insulin Sales by Application (2027-2032) & (K Units) Table 141. North America Short-acting Insulin Sales Price by Application (2021-2026) & (US$/Unit) Table 142. North America Short-acting Insulin Sales Price by Application (2027-2032) & (US$/Unit) Table 143. North America Short-acting Insulin Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. North America Short-acting Insulin Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 145. North America Short-acting Insulin Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 146. North America Short-acting Insulin Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 147. North America Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 148. North America Short-acting Insulin Sales by Country (2027-2032) & (K Units) Table 149. North America Short-acting Insulin Sales Price by Country (2021-2026) & (US$/Unit) Table 150. North America Short-acting Insulin Sales Price by Country (2027-2032) & (US$/Unit) Table 151. United States Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 152. Canada Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 153. Mexico Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 154. Europe Short-acting Insulin Revenue by Type (2021-2026) & (US$ Million) Table 155. Europe Short-acting Insulin Revenue by Type (2027-2032) & (US$ Million) Table 156. Europe Short-acting Insulin Sales by Type (2021-2026) & (K Units) Table 157. Europe Short-acting Insulin Sales by Type (2027-2032) & (K Units) Table 158. Europe Short-acting Insulin Sales Price by Type (2021-2026) & (US$/Unit) Table 159. Europe Short-acting Insulin Sales Price by Type (2027-2032) & (US$/Unit) Table 160. Europe Short-acting Insulin Revenue by Application (2021-2026) & (US$ Million) Table 161. Europe Short-acting Insulin Revenue by Application (2027-2032) & (US$ Million) Table 162. Europe Short-acting Insulin Sales by Application (2021-2026) & (K Units) Table 163. Europe Short-acting Insulin Sales by Application (2027-2032) & (K Units) Table 164. Europe Short-acting Insulin Sales Price by Application (2021-2026) & (US$/Unit) Table 165. Europe Short-acting Insulin Sales Price by Application (2027-2032) & (US$/Unit) Table 166. Europe Short-acting Insulin Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 167. Europe Short-acting Insulin Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 168. Europe Short-acting Insulin Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 169. Europe Short-acting Insulin Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 170. Europe Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 171. Europe Short-acting Insulin Sales by Country (2027-2032) & (K Units) Table 172. Europe Short-acting Insulin Sales Price by Country (2021-2026) & (US$/Unit) Table 173. Europe Short-acting Insulin Sales Price by Country (2027-2032) & (US$/Unit) Table 174. Germany Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 175. France Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 176. U.K. Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 177. Italy Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 178. Russia Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 179. Spain Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 180. Netherlands Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 181. Switzerland Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 182. Sweden Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 183. Poland Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 184. China Short-acting Insulin Revenue by Type (2021-2026) & (US$ Million) Table 185. China Short-acting Insulin Revenue by Type (2027-2032) & (US$ Million) Table 186. China Short-acting Insulin Sales by Type (2021-2026) & (K Units) Table 187. China Short-acting Insulin Sales by Type (2027-2032) & (K Units) Table 188. China Short-acting Insulin Sales Price by Type (2021-2026) & (US$/Unit) Table 189. China Short-acting Insulin Sales Price by Type (2027-2032) & (US$/Unit) Table 190. China Short-acting Insulin Revenue by Application (2021-2026) & (US$ Million) Table 191. China Short-acting Insulin Revenue by Application (2027-2032) & (US$ Million) Table 192. China Short-acting Insulin Sales by Application (2021-2026) & (K Units) Table 193. China Short-acting Insulin Sales by Application (2027-2032) & (K Units) Table 194. China Short-acting Insulin Sales Price by Application (2021-2026) & (US$/Unit) Table 195. China Short-acting Insulin Sales Price by Application (2027-2032) & (US$/Unit) Table 196. Asia Short-acting Insulin Revenue by Type (2021-2026) & (US$ Million) Table 197. Asia Short-acting Insulin Revenue by Type (2027-2032) & (US$ Million) Table 198. Asia Short-acting Insulin Sales by Type (2021-2026) & (K Units) Table 199. Asia Short-acting Insulin Sales by Type (2027-2032) & (K Units) Table 200. Asia Short-acting Insulin Sales Price by Type (2021-2026) & (US$/Unit) Table 201. Asia Short-acting Insulin Sales Price by Type (2027-2032) & (US$/Unit) Table 202. Asia Short-acting Insulin Revenue by Application (2021-2026) & (US$ Million) Table 203. Asia Short-acting Insulin Revenue by Application (2027-2032) & (US$ Million) Table 204. Asia Short-acting Insulin Sales by Application (2021-2026) & (K Units) Table 205. Asia Short-acting Insulin Sales by Application (2027-2032) & (K Units) Table 206. Asia Short-acting Insulin Sales Price by Application (2021-2026) & (US$/Unit) Table 207. Asia Short-acting Insulin Sales Price by Application (2027-2032) & (US$/Unit) Table 208. Asia Short-acting Insulin Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 209. Asia Short-acting Insulin Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 210. Asia Short-acting Insulin Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 211. Asia Short-acting Insulin Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 212. Asia Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 213. Asia Short-acting Insulin Sales by Country (2027-2032) & (K Units) Table 214. Asia Short-acting Insulin Sales Price by Country (2021-2026) & (US$/Unit) Table 215. Asia Short-acting Insulin Sales Price by Country (2027-2032) & (US$/Unit) Table 216. Japan Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 217. South Korea Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 218. India Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 219. Australia Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 220. Taiwan Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 221. Southeast Asia Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 222. SAMEA Short-acting Insulin Revenue by Type (2021-2026) & (US$ Million) Table 223. SAMEA Short-acting Insulin Revenue by Type (2027-2032) & (US$ Million) Table 224. SAMEA Short-acting Insulin Sales by Type (2021-2026) & (K Units) Table 225. SAMEA Short-acting Insulin Sales by Type (2027-2032) & (K Units) Table 226. SAMEA Short-acting Insulin Sales Price by Type (2021-2026) & (US$/Unit) Table 227. SAMEA Short-acting Insulin Sales Price by Type (2027-2032) & (US$/Unit) Table 228. SAMEA Short-acting Insulin Revenue by Application (2021-2026) & (US$ Million) Table 229. SAMEA Short-acting Insulin Revenue by Application (2027-2032) & (US$ Million) Table 230. SAMEA Short-acting Insulin Sales by Application (2021-2026) & (K Units) Table 231. SAMEA Short-acting Insulin Sales by Application (2027-2032) & (K Units) Table 232. SAMEA Short-acting Insulin Sales Price by Application (2021-2026) & (US$/Unit) Table 233. SAMEA Short-acting Insulin Sales Price by Application (2027-2032) & (US$/Unit) Table 234. SAMEA Short-acting Insulin Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 235. SAMEA Short-acting Insulin Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 236. SAMEA Short-acting Insulin Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 237. SAMEA Short-acting Insulin Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 238. SAMEA Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 239. SAMEA Short-acting Insulin Sales by Country (2027-2032) & (K Units) Table 240. SAMEA Short-acting Insulin Sales Price by Country (2021-2026) & (US$/Unit) Table 241. SAMEA Short-acting Insulin Sales Price by Country (2027-2032) & (US$/Unit) Table 242. Brazil Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 243. Argentina Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 244. Chile Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 245. Colombia Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 246. Peru Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 247. Saudi Arabia Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 248. Israel Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 249. UAE Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 250. Turkey Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 251. Iran Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 252. Egypt Short-acting Insulin Revenue (2021-2032) & (US$ Million) Table 253. Key Raw Materials Table 254. Raw Materials Key Suppliers Table 255. Short-acting Insulin Distributors List Table 256. Short-acting Insulin Customers List Table 257. Research Programs/Design for This Report Table 258. Authors List of This Report Table 259. Secondary Sources Table 260. Primary Sources List of Figures Figure 1. Short-acting Insulin Image Figure 2. Global Short-acting Insulin Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Short-acting Insulin Market Size Share 2021 VS 2025 VS 2032 Figure 4. Regular Insulin Image Figure 5. Biosynthetic Human Insulin Image Figure 6. Recombinant Human Insulin Image Figure 7. Other Image Figure 8. Global Short-acting Insulin Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Short-acting Insulin Market Size Share 2021 VS 2025 VS 2032 Figure 10. Type 2 Diabetes Image Figure 11. Type 1 Diabetes Image Figure 12. Gestational Diabetes Image Figure 13. Complications of Diabetes Image Figure 14. Other Image Figure 15. Global Short-acting Insulin Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Short-acting Insulin Revenue (2021-2032) & (US$ Million) Figure 17. Global Short-acting Insulin Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Short-acting Insulin Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Short-acting Insulin Revenue Market Share by Region (2021-2032) Figure 20. Global Short-acting Insulin Sales (2021-2032) & (K Units) Figure 21. Global Short-acting Insulin Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 22. Global Short-acting Insulin Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Short-acting Insulin Sales YoY (2021-2032) & (K Units) Figure 24. Europe Short-acting Insulin Sales YoY (2021-2032) & (K Units) Figure 25. China Short-acting Insulin Sales YoY (2021-2032) & (K Units) Figure 26. Asia (Excluding China) Short-acting Insulin Sales YoY (2021-2032) & (K Units) Figure 27. South America, Middle East and Africa Short-acting Insulin Sales YoY (2021-2032) & (K Units) Figure 28. Global Short-acting Insulin Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Short-acting Insulin Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Short-acting Insulin Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Short-acting Insulin Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Short-acting Insulin Revenue Market Share by Type (2021-2032) Figure 34. Global Short-acting Insulin Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 35. Global Short-acting Insulin Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Short-acting Insulin Sales Market Share by Type (2021-2032) Figure 37. Global Short-acting Insulin Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Short-acting Insulin Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Short-acting Insulin Revenue Market Share by Application (2021-2032) Figure 40. Global Short-acting Insulin Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 41. Global Short-acting Insulin Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Short-acting Insulin Sales Market Share by Application (2021-2032) Figure 43. North America Short-acting Insulin Revenue Share by Type (2021-2032) Figure 44. North America Short-acting Insulin Sales Share by Type (2021-2032) Figure 45. North America Short-acting Insulin Revenue Share by Application (2021-2032) Figure 46. North America Short-acting Insulin Sales Share by Application (2021-2032) Figure 47. North America Short-acting Insulin Revenue Share by Country (2021-2032) Figure 48. North America Short-acting Insulin Sales Share by Country (2021-2032) Figure 49. Europe Short-acting Insulin Revenue Share by Type (2021-2032) Figure 50. Europe Short-acting Insulin Sales Share by Type (2021-2032) Figure 51. Europe Short-acting Insulin Revenue Share by Application (2021-2032) Figure 52. Europe Short-acting Insulin Sales Share by Application (2021-2032) Figure 53. Europe Short-acting Insulin Revenue Share by Country (2021-2032) Figure 54. Europe Short-acting Insulin Sales Share by Country (2021-2032) Figure 55. China Short-acting Insulin Revenue Share by Type (2021-2032) Figure 56. China Short-acting Insulin Sales Share by Type (2021-2032) Figure 57. China Short-acting Insulin Revenue Share by Application (2021-2032) Figure 58. China Short-acting Insulin Sales Share by Application (2021-2032) Figure 59. Asia Short-acting Insulin Revenue Share by Type (2021-2032) Figure 60. Asia Short-acting Insulin Sales Share by Type (2021-2032) Figure 61. Asia Short-acting Insulin Revenue Share by Application (2021-2032) Figure 62. Asia Short-acting Insulin Sales Share by Application (2021-2032) Figure 63. Asia Short-acting Insulin Revenue Share by Country (2021-2032) Figure 64. Asia Short-acting Insulin Sales Share by Country (2021-2032) Figure 65. SAMEA Short-acting Insulin Revenue Share by Type (2021-2032) Figure 66. SAMEA Short-acting Insulin Sales Share by Type (2021-2032) Figure 67. SAMEA Short-acting Insulin Revenue Share by Application (2021-2032) Figure 68. SAMEA Short-acting Insulin Sales Share by Application (2021-2032) Figure 69. SAMEA Short-acting Insulin Revenue Share by Country (2021-2032) Figure 70. SAMEA Short-acting Insulin Sales Share by Country (2021-2032) Figure 71. Short-acting Insulin Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Short-acting Insulin Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Regular Insulin
  • Biosynthetic Human Insulin
  • Recombinant Human Insulin
  • Other
Applications
  • Type 2 Diabetes
  • Type 1 Diabetes
  • Gestational Diabetes
  • Complications of Diabetes
  • Other
Companies covered
  • Zhuhai United Pharmaceutical
  • Wanbang Biopharmaceuticals
  • Sinovac Biotech
  • HTBT
  • Tonghua Dongbao Pharmaceutical
  • Wockhardt
  • Sanofi
  • Pfizer
  • Novo Nordisk
  • Eli Lilly
  • Biocon Biologics
  • Bayer
  • BASF
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Short-acting Insulin Market by Type
  3. 1.2.1 Global Short-acting Insulin Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Regular Insulin
  5. 1.2.3 Biosynthetic Human Insulin
  6. 1.2.4 Recombinant Human Insulin
  7. 1.2.5 Other
  8. 1.3 Short-acting Insulin Market by Application
  9. 1.3.1 Global Short-acting Insulin Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Type 2 Diabetes
  11. 1.3.3 Type 1 Diabetes
  12. 1.3.4 Gestational Diabetes
  13. 1.3.5 Complications of Diabetes
  14. 1.3.6 Other
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Short-acting Insulin Market Dynamics
  1. 2.1 Short-acting Insulin Industry Trends
  2. 2.2 Short-acting Insulin Industry Drivers
  3. 2.3 Short-acting Insulin Industry Opportunities and Challenges
  4. 2.4 Short-acting Insulin Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Short-acting Insulin Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Short-acting Insulin Revenue by Region
  3. 3.2.1 Global Short-acting Insulin Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Short-acting Insulin Revenue by Region (2021-2026)
  5. 3.2.3 Global Short-acting Insulin Revenue by Region (2027-2032)
  6. 3.2.4 Global Short-acting Insulin Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Short-acting Insulin Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Short-acting Insulin Sales by Region
  9. 3.4.1 Global Short-acting Insulin Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Short-acting Insulin Sales by Region (2021-2026)
  11. 3.4.3 Global Short-acting Insulin Sales by Region (2027-2032)
  12. 3.4.4 Global Short-acting Insulin Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Short-acting Insulin Revenue by Manufacturers
  2. 4.1.1 Global Short-acting Insulin Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Short-acting Insulin Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Short-acting Insulin Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Short-acting Insulin Sales by Manufacturers
  6. 4.2.1 Global Short-acting Insulin Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Short-acting Insulin Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Short-acting Insulin Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Short-acting Insulin Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Short-acting Insulin Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Short-acting Insulin Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Short-acting Insulin Manufacturers, Product Type & Application
  13. 4.7 Global Short-acting Insulin Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Short-acting Insulin Market CR5 and HHI
  16. 4.8.2 2025 Short-acting Insulin Tier 1, Tier 2, and Tier 3
5 Short-acting Insulin Market by Type
  1. 5.1 Global Short-acting Insulin Revenue by Type
  2. 5.1.1 Global Short-acting Insulin Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Short-acting Insulin Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Short-acting Insulin Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Short-acting Insulin Sales by Type
  6. 5.2.1 Global Short-acting Insulin Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Short-acting Insulin Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Short-acting Insulin Sales Market Share by Type (2021-2032)
  9. 5.3 Global Short-acting Insulin Price by Type
6 Short-acting Insulin Market by Application
  1. 6.1 Global Short-acting Insulin Revenue by Application
  2. 6.1.1 Global Short-acting Insulin Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Short-acting Insulin Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Short-acting Insulin Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Short-acting Insulin Sales by Application
  6. 6.2.1 Global Short-acting Insulin Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Short-acting Insulin Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Short-acting Insulin Sales Market Share by Application (2021-2032)
  9. 6.3 Global Short-acting Insulin Price by Application
7 Company Profiles
  1. 7.1 Zhuhai United Pharmaceutical
  2. 7.1.1 Zhuhai United Pharmaceutical Company Information
  3. 7.1.2 Zhuhai United Pharmaceutical Business Overview
  4. 7.1.3 Zhuhai United Pharmaceutical Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolio
  6. 7.1.5 Zhuhai United Pharmaceutical Recent Developments
  7. 7.2 Wanbang Biopharmaceuticals
  8. 7.2.1 Wanbang Biopharmaceuticals Company Information
  9. 7.2.2 Wanbang Biopharmaceuticals Business Overview
  10. 7.2.3 Wanbang Biopharmaceuticals Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolio
  12. 7.2.5 Wanbang Biopharmaceuticals Recent Developments
  13. 7.3 Sinovac Biotech
  14. 7.3.1 Sinovac Biotech Company Information
  15. 7.3.2 Sinovac Biotech Business Overview
  16. 7.3.3 Sinovac Biotech Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Sinovac Biotech Short-acting Insulin Product Portfolio
  18. 7.3.5 Sinovac Biotech Recent Developments
  19. 7.4 HTBT
  20. 7.4.1 HTBT Company Information
  21. 7.4.2 HTBT Business Overview
  22. 7.4.3 HTBT Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 HTBT Short-acting Insulin Product Portfolio
  24. 7.4.5 HTBT Recent Developments
  25. 7.5 Tonghua Dongbao Pharmaceutical
  26. 7.5.1 Tonghua Dongbao Pharmaceutical Company Information
  27. 7.5.2 Tonghua Dongbao Pharmaceutical Business Overview
  28. 7.5.3 Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolio
  30. 7.5.5 Tonghua Dongbao Pharmaceutical Recent Developments
  31. 7.6 Wockhardt
  32. 7.6.1 Wockhardt Company Information
  33. 7.6.2 Wockhardt Business Overview
  34. 7.6.3 Wockhardt Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Wockhardt Short-acting Insulin Product Portfolio
  36. 7.6.5 Wockhardt Recent Developments
  37. 7.7 Sanofi
  38. 7.7.1 Sanofi Company Information
  39. 7.7.2 Sanofi Business Overview
  40. 7.7.3 Sanofi Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Sanofi Short-acting Insulin Product Portfolio
  42. 7.7.5 Sanofi Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Short-acting Insulin Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 Novo Nordisk
  50. 7.9.1 Novo Nordisk Company Information
  51. 7.9.2 Novo Nordisk Business Overview
  52. 7.9.3 Novo Nordisk Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Novo Nordisk Short-acting Insulin Product Portfolio
  54. 7.9.5 Novo Nordisk Recent Developments
  55. 7.10 Eli Lilly
  56. 7.10.1 Eli Lilly Company Information
  57. 7.10.2 Eli Lilly Business Overview
  58. 7.10.3 Eli Lilly Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Eli Lilly Short-acting Insulin Product Portfolio
  60. 7.10.5 Eli Lilly Recent Developments
  61. 7.11 Biocon Biologics
  62. 7.11.1 Biocon Biologics Company Information
  63. 7.11.2 Biocon Biologics Business Overview
  64. 7.11.3 Biocon Biologics Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Biocon Biologics Short-acting Insulin Product Portfolio
  66. 7.11.5 Biocon Biologics Recent Developments
  67. 7.12 Bayer
  68. 7.12.1 Bayer Company Information
  69. 7.12.2 Bayer Business Overview
  70. 7.12.3 Bayer Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Bayer Short-acting Insulin Product Portfolio
  72. 7.12.5 Bayer Recent Developments
  73. 7.13 BASF
  74. 7.13.1 BASF Company Information
  75. 7.13.2 BASF Business Overview
  76. 7.13.3 BASF Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 BASF Short-acting Insulin Product Portfolio
  78. 7.13.5 BASF Recent Developments
  79. 7.14 Abbott Laboratories
  80. 7.14.1 Abbott Laboratories Company Information
  81. 7.14.2 Abbott Laboratories Business Overview
  82. 7.14.3 Abbott Laboratories Short-acting Insulin Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Abbott Laboratories Short-acting Insulin Product Portfolio
  84. 7.14.5 Abbott Laboratories Recent Developments
8 North America
  1. 8.1 North America Short-acting Insulin Market Size by Type
  2. 8.1.1 North America Short-acting Insulin Revenue by Type (2021-2032)
  3. 8.1.2 North America Short-acting Insulin Sales by Type (2021-2032)
  4. 8.1.3 North America Short-acting Insulin Price by Type (2021-2032)
  5. 8.2 North America Short-acting Insulin Market Size by Application
  6. 8.2.1 North America Short-acting Insulin Revenue by Application (2021-2032)
  7. 8.2.2 North America Short-acting Insulin Sales by Application (2021-2032)
  8. 8.2.3 North America Short-acting Insulin Price by Application (2021-2032)
  9. 8.3 North America Short-acting Insulin Market Size by Country
  10. 8.3.1 North America Short-acting Insulin Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Short-acting Insulin Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Short-acting Insulin Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Short-acting Insulin Market Size by Type
  2. 9.1.1 Europe Short-acting Insulin Revenue by Type (2021-2032)
  3. 9.1.2 Europe Short-acting Insulin Sales by Type (2021-2032)
  4. 9.1.3 Europe Short-acting Insulin Price by Type (2021-2032)
  5. 9.2 Europe Short-acting Insulin Market Size by Application
  6. 9.2.1 Europe Short-acting Insulin Revenue by Application (2021-2032)
  7. 9.2.2 Europe Short-acting Insulin Sales by Application (2021-2032)
  8. 9.2.3 Europe Short-acting Insulin Price by Application (2021-2032)
  9. 9.3 Europe Short-acting Insulin Market Size by Country
  10. 9.3.1 Europe Short-acting Insulin Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Short-acting Insulin Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Short-acting Insulin Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Short-acting Insulin Market Size by Type
  2. 10.1.1 China Short-acting Insulin Revenue by Type (2021-2032)
  3. 10.1.2 China Short-acting Insulin Sales by Type (2021-2032)
  4. 10.1.3 China Short-acting Insulin Price by Type (2021-2032)
  5. 10.2 China Short-acting Insulin Market Size by Application
  6. 10.2.1 China Short-acting Insulin Revenue by Application (2021-2032)
  7. 10.2.2 China Short-acting Insulin Sales by Application (2021-2032)
  8. 10.2.3 China Short-acting Insulin Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Short-acting Insulin Market Size by Type
  2. 11.1.1 Asia Short-acting Insulin Revenue by Type (2021-2032)
  3. 11.1.2 Asia Short-acting Insulin Sales by Type (2021-2032)
  4. 11.1.3 Asia Short-acting Insulin Price by Type (2021-2032)
  5. 11.2 Asia Short-acting Insulin Market Size by Application
  6. 11.2.1 Asia Short-acting Insulin Revenue by Application (2021-2032)
  7. 11.2.2 Asia Short-acting Insulin Sales by Application (2021-2032)
  8. 11.2.3 Asia Short-acting Insulin Price by Application (2021-2032)
  9. 11.3 Asia Short-acting Insulin Market Size by Country
  10. 11.3.1 Asia Short-acting Insulin Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Short-acting Insulin Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Short-acting Insulin Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Short-acting Insulin Market Size by Type
  2. 12.1.1 SAMEA Short-acting Insulin Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Short-acting Insulin Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Short-acting Insulin Price by Type (2021-2032)
  5. 12.2 SAMEA Short-acting Insulin Market Size by Application
  6. 12.2.1 SAMEA Short-acting Insulin Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Short-acting Insulin Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Short-acting Insulin Price by Application (2021-2032)
  9. 12.3 SAMEA Short-acting Insulin Market Size by Country
  10. 12.3.1 SAMEA Short-acting Insulin Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Short-acting Insulin Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Short-acting Insulin Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Short-acting Insulin Value Chain Analysis
  2. 13.1.1 Short-acting Insulin Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Short-acting Insulin Production Mode & Process
  6. 13.2 Short-acting Insulin Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Short-acting Insulin Distributors
  9. 13.2.3 Short-acting Insulin Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst